One man was brain dead and three others faced possible permanent brain damage after volunteering to take part in a drug trial for a painkiller based on a natural brain compound similar to the active ingredient in marijuana, French authorities said on Friday.
The Paris prosecutor’s office opened an investigation into what French Minister of Health Marisol Touraine called “an accident of exceptional gravity” at a clinical trial lab in the western French city of Rennes.
The trial involved 90 healthy volunteers who were given the experimental drug in varying doses at different times, she told reporters at a news conference in Rennes.
Photo: AP
Six male volunteers between 28 and 49 years old have since been hospitalized, including one man now classified as brain dead, Touraine said, adding that the other 83 volunteers were being contacted.
Calling the case “unprecedented,” Touraine said she was “deeply moved” by the suffering of the victims, who she met with earlier on Friday, along with their families.
“We’ll do everything to understand what happened,” she said. “I don’t know of any other event like this.”
The drug trial for the six hospitalized men began on Jan. 7 and was halted on Monday, a day after the first volunteer fell ill.
The chief neuroscientist at the hospital in Rennes, Gilles Edan, said in addition to the brain-dead man, three other men could have “irreversible” brain damage.
A fifth man is suffering from neurological problems and a sixth man is being kept in the hospital, but is in less critical condition, he said.
Edan said there is no known way to reverse the effects of the experimental drug, which was given orally to healthy volunteers as part of a Phase 1 trial by Biotrial, a drug evaluation company based in Rennes, on behalf of the Portuguese pharmaceutical company Bial.
Touraine said that in addition to treating pain, the drug was intended to ease mood and anxiety troubles, as well as motor problems linked to neurodegenerative illnesses, by acting on the endocannabinoid system. In this system, natural brain compounds act on specific receptors to exert their effects. The experimental drug is based on a natural brain compound similar to the active ingredient in marijuana.
Touraine said the drug was not based on marijuana itself, as some media reports had claimed.
“This drug is not cannabis. It is not derived from cannabis. It works on the natural system that helps fight pain,” she said, adding that no drug currently on the market was implicated in the failed trial. Bial, the Portuguese drug producer, said on Friday that 108 healthy people had already taken part in trials involving the drug and had no moderate or serious reactions. Bial added that initial testing for the drug started in June following toxicology tests.
It is rare for volunteers to fall seriously ill during Phase 1 trials, which study safe usage, side effects and other measures on healthy volunteers, rather than drug effectiveness. Researchers generally start with the lowest possible dose after extensive tests in animals, and Touraine said the drug had previously been tested on chimpanzees and other animals.
In 2006, Britain saw a similar incident, when six previously healthy men were treated for organ failure only hours after being given an experimental drug targeting the immune system.
That prompted a review of procedures and resulted in the British regulatory agency imposing new testing standards, including recommendations to use the lowest possible dose and to test new drugs only on one person at a time.
The six men in Britain now apparently have a higher risk of cancer and autoimmune diseases tied to their exposure to the experimental drug.
Ben Whalley, a neuropharmacology professor at Britain’s University of Reading, said that standardized regulations for clinical trials are “largely the same” across Europe.
“However, like any safeguard, these minimize risk, rather than abolish it,” Whalley said in a statement. “There is an inherent risk in exposing people to any new compound.”
Chinese President Xi Jinping (習近平) is to visit Russia next month for a summit of the BRICS bloc of developing economies, Chinese Minister of Foreign Affairs Wang Yi (王毅) said on Thursday, a move that comes as Moscow and Beijing seek to counter the West’s global influence. Xi’s visit to Russia would be his second since the Kremlin sent troops into Ukraine in February 2022. China claims to take a neutral position in the conflict, but it has backed the Kremlin’s contentions that Russia’s action was provoked by the West, and it continues to supply key components needed by Moscow for
Japan scrambled fighter jets after Russian aircraft flew around the archipelago for the first time in five years, Tokyo said yesterday. From Thursday morning to afternoon, the Russian Tu-142 aircraft flew from the sea between Japan and South Korea toward the southern Okinawa region, the Japanese Ministry of Defense said in a statement. They then traveled north over the Pacific Ocean and finished their journey off the northern island of Hokkaido, it added. The planes did not enter Japanese airspace, but flew over an area subject to a territorial dispute between Japan and Russia, a ministry official said. “In response, we mobilized Air Self-Defense
CRITICISM: ‘One has to choose the lesser of two evils,’ Pope Francis said, as he criticized Trump’s anti-immigrant policies and Harris’ pro-choice position Pope Francis on Friday accused both former US president Donald Trump and US Vice President Kamala Harris of being “against life” as he returned to Rome from a 12-day tour of the Asia-Pacific region. The 87-year-old pontiff’s comments on the US presidential hopefuls came as he defied health concerns to connect with believers from the jungle of Papua New Guinea to the skyscrapers of Singapore. It was Francis’ longest trip in duration and distance since becoming head of the world’s nearly 1.4 billion Roman Catholics more than 11 years ago. Despite the marathon visit, he held a long and spirited
China would train thousands of foreign law enforcement officers to see the world order “develop in a more fair, reasonable and efficient direction,” its minister for public security has said. “We will [also] send police consultants to countries in need to conduct training to help them quickly and effectively improve their law enforcement capabilities,” Chinese Minister of Public Security Wang Xiaohong (王小洪) told an annual global security forum. Wang made the announcement in the eastern city of Lianyungang on Monday in front of law enforcement representatives from 122 countries, regions and international organizations such as Interpol. The forum is part of ongoing